We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Aptiv (APTV) Beats Q3 Earnings and Revenue Estimates
Read MoreHide Full Article
Aptiv PLC (APTV - Free Report) reported third-quarter 2018 (ended Sep 30, 2018) earnings per share of $1.24 (on an adjusted basis), beating the Zacks Consensus Estimate of $1.20.
How Was the Estimate Revision Trend?
Investors should note that the earnings estimate revisions for Aptiv depicted a pessimistic picture prior to the earnings release. The stock had seen the Zacks Consensus Estimate for third-quarter 2018 earnings move down 3.2% over the last 60 days.
However, the company has an impressive earnings history having outperformed the Zacks Consensus Estimate in three of the last four quarters with an average beat of 3.1%.
Revenues Higher Than Expected
Aptiv recorded total revenues of $3.5 billion which outperformed the Zacks Consensus Estimate of $3.4 billion.
Key Stats to Note: Aptiv trimmed its 2018 guidance.The company anticipates earnings to be in the range of $5.11 - $5.17 per share compared with the prior guidance of $5.30-$5.40 per share. Net sales are expected between $14.275 billion and $14.375 billion compared with $14.350 billion and $14.550 billion anticipated earlier.
Check back later for our full write up on this Aptiv earnings report later!
3 Medical Stocks to Buy Now
The greatest discovery in this century of biology is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating revenue, and cures for a variety of deadly diseases are in the pipeline.
So are big potential profits for early investors. Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it.
Image: Bigstock
Aptiv (APTV) Beats Q3 Earnings and Revenue Estimates
Aptiv PLC (APTV - Free Report) reported third-quarter 2018 (ended Sep 30, 2018) earnings per share of $1.24 (on an adjusted basis), beating the Zacks Consensus Estimate of $1.20.
How Was the Estimate Revision Trend?
Investors should note that the earnings estimate revisions for Aptiv depicted a pessimistic picture prior to the earnings release. The stock had seen the Zacks Consensus Estimate for third-quarter 2018 earnings move down 3.2% over the last 60 days.
However, the company has an impressive earnings history having outperformed the Zacks Consensus Estimate in three of the last four quarters with an average beat of 3.1%.
Revenues Higher Than Expected
Aptiv recorded total revenues of $3.5 billion which outperformed the Zacks Consensus Estimate of $3.4 billion.
Key Stats to Note: Aptiv trimmed its 2018 guidance.The company anticipates earnings to be in the range of $5.11 - $5.17 per share compared with the prior guidance of $5.30-$5.40 per share. Net sales are expected between $14.275 billion and $14.375 billion compared with $14.350 billion and $14.550 billion anticipated earlier.
Aptiv PLC Price
Aptiv PLC Price | Aptiv PLC Quote
Zacks Rank: Currently, Aptiv has a Zacks Rank #3 (Hold) but that could change following the company’s earnings report which was just released. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Check back later for our full write up on this Aptiv earnings report later!
3 Medical Stocks to Buy Now
The greatest discovery in this century of biology is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating revenue, and cures for a variety of deadly diseases are in the pipeline.
So are big potential profits for early investors. Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it.
See them today for free >>